The estimated Net Worth of Barbara Klencke is at least 1.25 百万$ dollars as of 18 August 2020. Barbara Klencke owns over 9,275 units of Sierra Oncology Inc stock worth over 274,950$ and over the last 8 years he sold SRRA stock worth over 0$. In addition, he makes 971,397$ as Chief Development Officer at Sierra Oncology Inc.
Sign up
Barbara Klencke SRRA stock SEC Form 4 insiders trading
Barbara has made over 2 trades of the Sierra Oncology Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 9,275 units of SRRA stock worth 113,433$ on 18 August 2020.
The largest trade he's ever made was buying 229,000 units of Sierra Oncology Inc stock on 22 August 2019 worth over 100,760$. On average, Barbara trades about 18,329 units every 28 days since 2017. As of 18 August 2020 he still owns at least 5,000 units of Sierra Oncology Inc stock.
You can see the complete history of Barbara Klencke stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Barbara Klencke biography
Dr. Barbara Klencke M.D. serves as Chief Development Officer of the Company. Previously, Dr. Klencke served as the Senior Vice President, Development at Onyx Pharmaceuticals, a biopharmaceutical company and a subsidiary of Amgen Inc., from January 2011 to June 2015, and as the Group Medical Director in Product Development, Oncology at Genentech, Inc., a biotechnology company, from July 2003 to January 2011. Prior to that, Dr. Klencke served as the Medical Director at Chiron Corporation, a biotechnology company later acquired by Novartis International AG, and as an assistant professor of medicine at the University of California, San Francisco Medical Center. Dr. Klencke currently serves on the Board of Directors of Lexent Bio. Dr. Klencke holds a B.S. from Indiana University and an M.D. from the University of California, Davis.
What is the salary of Barbara Klencke?
As the Chief Development Officer of Sierra Oncology Inc, the total compensation of Barbara Klencke at Sierra Oncology Inc is 971,397$. There are no executives at Sierra Oncology Inc getting paid more.
How old is Barbara Klencke?
Barbara Klencke is 62, he's been the Chief Development Officer of Sierra Oncology Inc since 2015. There are 5 older and 12 younger executives at Sierra Oncology Inc. The oldest executive at Sierra Oncology Inc is Robert Pelzer, 66, who is the Independent Chairman of the Board.
What's Barbara Klencke's mailing address?
Barbara's mailing address filed with the SEC is C/O XENCOR, INC., 465 N HALSTEAD STREET, SUITE 200, PASADENA, CA, 91107.
Insiders trading at Sierra Oncology Inc
Over the last 8 years, insiders at Sierra Oncology Inc have traded over 0$ worth of Sierra Oncology Inc stock and bought 8,528,701 units worth 69,515,388$ . The most active insiders traders include Andrew Sinclair、Llp Abingworth、James N Topper. On average, Sierra Oncology Inc executives and independent directors trade stock every 85 days with the average trade being worth of 21,400,348$. The most recent stock trade was executed by William D. Turner on 5 April 2022, trading 6,447 units of SRRA stock currently worth 77,686$.
What does Sierra Oncology Inc do?
Sierra Oncology is a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer. Sierra Oncology harnesses its deep scientific expertise to identify compounds that target the root cause of disease to advance targeted therapies with assets on the leading edge of cancer biology. Its team takes an evidence-based approach to understand the limitations of current treatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact.
What does Sierra Oncology Inc's logo look like?
Complete history of Barbara Klencke stock trades at Sierra Oncology Inc、Xencor Inc
Sierra Oncology Inc executives and stock owners
Sierra Oncology Inc executives and other stock owners filed with the SEC include:
-
Barbara Klencke,
Chief Development Officer -
Mark Kowalski,
Chief Medical Officer -
Sukhi Jagpal,
Chief Financial Officer -
Dr. Stephen George Dilly M.B.B.S, Ph.D.,
Pres, CEO & Director -
Dr. Barbara J. Klencke M.D.,
Chief Medical Officer -
Dr. Mark M. Kowalski M.D., Ph.D.,
Chief of Research & Early Devel. -
Robert Pelzer,
Independent Chairman of the Board -
James Smith,
Vice President Corporate Affairs -
Andrew Sinclair,
Independent Director -
Josh Richardson,
Independent Director -
Jeffrey Cooper,
Independent Director -
Mona Ashiya,
Independent Director -
Andrew Allen,
Independent Director -
Gaurav Aggarwal,
Independent Director -
Craig Collard,
Director -
William Turner,
Chief Regulatory and Technical Operations Officer -
Kevin Norrett,
Chief Business Officer -
Christina Thomson,
General Counsel -
Stephen Dilly,
President, Chief Executive Officer, Director -
Kevin Norrett M.B.A., M.S.,
Chief Bus. Officer -
William D. Turner,
Chief Regulatory & Technical Operations Officer -
Christina Thomson J.D., M.S.,
Gen. Counsel, Chief Compliance Officer & Sec. -
Sukhi Jagpal CA, CPA, CBV, MBA,
Chief Financial Officer -
Daniel Estes,
Director -
James N Topper,
Director -
Nicholas Glover,
CEO and President -
Nicole Onetto,
Director -
Tran Nguyen,
Director -
Donald R Parfet,
Director -
Angie You,
Chief Bus. & Strat. Officer -
Capital Partners Iii, Llc L...,
-
Christian Hassig,
Chief Scientific Officer -
Opportunity, Llc Vivo Oppor...,
-
Advisors Llcorbimed Capital...,
-
Opportunity, Llc Vivo Oppor...,
-
Advisors Llc Orbi Med Capit...,
-
Georgia Erbez,
Director -
Christy J. Oliger,
Director -
Llp Abingworth,
10% owner -
Mary Christina Thomson,
General Counsel -
Advisors Llc Orbi Med Capit...,